Eliem Therapeutics Inc ELYM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.50
- Day Range
- $4.84–5.63
- 52-Week Range
- $2.35–11.55
- Bid/Ask
- $5.00 / $5.14
- Market Cap
- $335.30 Mil
- Volume/Avg
- 1.3 Mil / 472,663
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Its main drug candidate is ETX-155 for major depressive disorder (MDD) and focal onset seizures (FOS).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.eliemtx.com
Comparables
Valuation
|
Metric
|
ELYM
|
AVIR
|
CTNM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.50 | 0.61 | 2.21 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ELYM
AVIR
CTNM
Financial Strength
|
Metric
|
ELYM
|
AVIR
|
CTNM
|
|---|---|---|---|
Quick Ratio | 59.65 | 18.87 | 58.48 |
Current Ratio | 60.41 | 19.02 | 58.92 |
Interest Coverage | — | — | — |
Quick Ratio
ELYM
AVIR
CTNM
Profitability
|
Metric
|
ELYM
|
AVIR
|
CTNM
|
|---|---|---|---|
Return on Assets (Normalized) | −45.38% | −23.62% | −18.15% |
Return on Equity (Normalized) | −46.50% | −25.11% | −871.68% |
Return on Invested Capital (Normalized) | −46.38% | −29.21% | −892.99% |
Return on Assets
ELYM
AVIR
CTNM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ctxlswylzl | Xzyqp | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rczchpwsm | Ncpkdvy | $119.6 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ylgckwvmq | Qqqqk | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kbcsfbrc | Kpkkwzk | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Yzmvqbmnk | Mdwln | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Xxbvghfr | Ltqwq | $28.0 Bil | |||
| Moderna Inc
MRNA
| Ggcvlmf | Fvfcg | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Lskdpqcy | Ltxtm | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ntnfnkb | Ptgdkn | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Hxzckqbh | Rhnrqnw | $12.6 Bil |
United States